ArticleInternational journal of laboratory hematology2022
Diagnostic value of white blood cell parameters for COVID-19: Is there a role for HFLC and IG?
Article in International journal of laboratory hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Predictive triage for testing may improve control of a COVID-19 epidemic while reducing testing requirements.Archives of public health = Archives belges de sante publique · 2026Article
- Hematological, inflammatory and serological responses among COVID-19 patients admitted to intensive care unit.Future science OA · 2024Article
- Eosinophil granulocytes in chronic inflammatory respiratory diseases and CRSwNP: Function, immunological basis, and clinical significance.Allergologie select · 2024Review
- Article
- Clinical Characteristics and Serum Cytokines Profiling in Hospitalized COVID-19 Patients in Lebanon.Journal of immunology research · 2023Article
- Immature granulocytes: Innovative biomarker for SARS‑CoV‑2 infection.Molecular medicine reports · 2022Article
- Diagnostic value of white blood cell parameters for COVID-19: Is there a role for HFLC and IG?International journal of laboratory hematology · 2022Article
- Use of Machine Learning and Routine Laboratory Tests for Diabetes Mellitus Screening.BioMed research international · 2022Article
- Differences in Clinical and Laboratory Features of Pregnant and Non-Pregnant Female with Hospitalized COVID-19.Iranian journal of nursing and midwifery researchArticle
- Use of Artificial Intelligence in the Search for New Information Through Routine Laboratory Tests: Systematic Review.JMIR bioinformatics and biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAs the Coronavirus disease 2019 (COVID-19) pandemic is still ongoing with patients overwhelming healthcare facilities, we aimed to investigate the ability of white blood cell count (WBC) and their subsets, high fluorescence lymphocyte cells (HFLC), immature granulocyte count (IG), and C-reactive protein (CRP) to aid diagnosis of COVID-19 during the triage process and as indicators of disease progression to serious and critical condition.
methodsWe collected clinical and laboratory data of patients, suspected COVID-19 cases, admitted at the emergency department of University General Hospital of Ioannina (Ioannina, Greece). We selected 197 negative and 368 positive cases, confirmed by polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. COVID-19 cases were classified into mild, serious, and critical disease. Receiver operating characteristic curve and binary logistic regression analysis were utilized for assessing the diagnosing ability of biomarkers.
resultsWBC, neutrophil count (NEUT), and HFLC can discriminate efficiently negative cases from mild and serious COVID-19, whereas eosinopenia and basopenia are early indicators of the disease. The combined WBC-HFLC marker is the best diagnostic marker for both mild (sensitivity: 90.6% and specificity: 64.1%) and serious (sensitivity: 90.3% and specificity: 73.4%) disease. CRP and Lymphocyte count are early indicators of progression to serious disease whereas WBC, NEUT, IG, and neutrophil-to-lymphocyte ratio are the best indicators of critical disease.
conclusionLymphopenia is not useful in screening patients with COVID-19. HFLC is a good diagnostic marker for mild and serious disease either as a single marker or combined with WBC whereas IG is a good indicator of progression to critical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.